Press release
Exophthalmos Market to Reach USD 4.0 Billion by 2034
Exophthalmos Market
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72255
Growing awareness of thyroid disorders, autoimmune conditions, and orbital inflammatory diseases, coupled with the availability of advanced biologic therapies and surgical interventions, is driving growth in the exophthalmos treatment market.
Market Overview
• Market Size (2024): USD 1.9 billion
• Forecast (2034): USD 4.0 billion
• CAGR (2025-2034): 7.9%
Key Highlights:
• Rising prevalence of thyroid eye disease (TED) as the primary cause of exophthalmos.
• Increasing adoption of biologic therapies (e.g., teprotumumab) for TED.
• Growing demand for orbital decompression surgeries in severe cases.
• Expansion of multidisciplinary care involving endocrinology and ophthalmology.
Segmentation Analysis
By Treatment Type:
• Medication
o Corticosteroids
o Biologic Therapies (anti-IGF-1R, anti-TNF)
o Immunosuppressive Agents
• Surgical
o Orbital Decompression
o Eyelid Surgery
o Strabismus Surgery
• Adjunctive Therapies (lubricants, supportive care)
By Cause/Indication:
• Thyroid Eye Disease (TED) - dominant
• Orbital Tumors
• Trauma-Induced Exophthalmos
• Inflammatory Causes (sarcoidosis, orbital cellulitis)
• Others
By End Use:
• Hospitals
• Specialty Eye Clinics
• Ambulatory Surgical Centers
• Research & Academic Institutes
Segmentation Summary:
Thyroid eye disease-related exophthalmos dominates the market, with biologics and orbital decompression surgery being the mainstay treatment strategies.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72255/exophthalmos-market
Regional Analysis
North America
• Largest market (~41% share in 2024).
• High prevalence of thyroid disorders and autoimmune diseases.
• FDA approval of biologics like Tepezza (teprotumumab) boosting adoption.
Europe
• ~30% share.
• Strong demand for biologics and surgical interventions in Germany, UK, and France.
• EU support for rare autoimmune ophthalmic conditions.
Asia-Pacific
• Fastest-growing region, CAGR ~8.6%.
• Large patient population with rising incidence of thyroid disorders.
• Expanding access to advanced biologics in Japan, China, and India.
Latin America
• Brazil and Mexico driving adoption, though cost remains a barrier.
Middle East & Africa
• GCC countries increasing access to thyroid disease treatments.
• Limited advanced ophthalmology infrastructure in most low-income nations.
Regional Summary:
North America and Europe dominate the market today, but Asia-Pacific will grow fastest, driven by rising autoimmune disease burden and better treatment access.
Market Dynamics
Key Growth Drivers:
• Rising prevalence of thyroid disorders worldwide.
• Strong clinical success of biologics like teprotumumab in TED.
• Growing awareness and early diagnosis of autoimmune-related exophthalmos.
• Expansion of multidisciplinary care centers for orbital diseases.
Key Challenges:
• High cost of biologics limiting access.
• Limited availability of skilled orbital surgeons in some regions.
• Risks of recurrence and complications post-surgery.
• Uneven reimbursement across geographies.
Latest Trends:
• Development of next-generation biologics beyond teprotumumab.
• Increased use of orbital imaging and AI tools for surgical planning.
• Growth of tele-ophthalmology for early diagnosis and follow-up.
• Patient-centric therapies focusing on both functional and cosmetic outcomes.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72255
Competitor Analysis
Major Players in the Market:
• Horizon Therapeutics plc (Amgen Inc.) - Tepezza for thyroid eye disease.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• Johnson & Johnson Vision
• Bausch + Lomb
• Alcon Inc.
• Medtronic plc (surgical devices for orbital procedures)
Competitive Summary:
Horizon Therapeutics (Amgen) dominates with Tepezza, the first FDA-approved biologic for TED-related exophthalmos. Novartis, Roche, and Regeneron are investing in next-gen biologics. J&J Vision, Alcon, and Bausch provide surgical and ocular care solutions, while Medtronic supports orbital surgery technologies.
Conclusion
The Exophthalmos Market, valued at USD 1.9 billion in 2024, is projected to reach USD 4.0 billion by 2034, growing at a CAGR of 7.9%.
Key Takeaways:
• Thyroid eye disease drives the majority of cases and market demand.
• Biologics like teprotumumab are revolutionizing treatment.
• North America and Europe lead adoption, but Asia-Pacific shows the fastest growth.
• Surgical innovation and regenerative medicine represent future opportunities.
Over the next decade, exophthalmos management will shift from primarily surgical approaches to targeted biologics and personalized therapies, ensuring both improved vision outcomes and better quality of life for patients.
This report is also available in the following languages : Japanese (眼球突出市場), Korean (안구돌출증 시장), Chinese (突眼市场), French (Marché de l'exophtalmie), German (Exophthalmus-Markt), and Italian (Mercato dell'esoftalmo), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72255/exophthalmos-market#request-a-sample
Our More Reports:
Cell Line Characterization and Cell Line Development Market
https://exactitudeconsultancy.com/reports/72892/cell-line-characterization-and-cell-line-development-market
Fill Finish Pharmaceutical Contract Manufacturing Market
https://exactitudeconsultancy.com/reports/72893/fill-finish-pharmaceutical-contract-manufacturing-market
T-cell Lymphoma Market
https://exactitudeconsultancy.com/reports/72894/t-cell-lymphoma-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exophthalmos Market to Reach USD 4.0 Billion by 2034 here
News-ID: 4194309 • Views: …
More Releases from Exactitude Consultancy
Corneal Epithelial Defect Market to Reach USD 2.5 Billion by 2034
Corneal epithelial defects (CEDs) are disruptions in the corneal epithelium, often caused by trauma, infections, contact lens misuse, refractive surgery, or underlying systemic conditions like diabetes and autoimmune disorders. Left untreated, CEDs can lead to infections, scarring, recurrent erosions, and vision loss, making early diagnosis and treatment crucial.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72253
With the increasing global burden of ocular surface diseases, rising cataract/refractive surgeries, and corneal…
Cataract Surgery Complications Market Projected to Grow at 7.5% CAGR
Introduction
Cataract surgery is the most common ophthalmic surgical procedure worldwide, with millions of procedures performed annually. While advances in surgical techniques and intraocular lens (IOL) technologies have improved outcomes, post-operative complications such as posterior capsule opacification (PCO), cystoid macular edema (CME), endophthalmitis, retinal detachment, and corneal edema remain significant clinical and economic concerns.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72247
The growing global population, increasing number of elderly patients,…
Anterior Uveitis Market Projected to Grow at 7.6% CAGR, Reaching USD 3.4 Billion …
Introduction
Anterior uveitis is the most common form of uveitis, characterized by inflammation of the uvea's front portion, primarily the iris and ciliary body. It can be caused by autoimmune disorders, infections, or trauma, and is a leading cause of ocular morbidity and preventable blindness.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72245
With the increasing prevalence of autoimmune diseases (like ankylosing spondylitis and juvenile idiopathic arthritis), infectious triggers, and lifestyle…
Giant Papillary Conjunctivitis Market to Reach USD 1.6 Billion by 2034
Giant papillary conjunctivitis (GPC) is a chronic inflammatory condition of the conjunctiva, characterized by the presence of large papillae on the inner eyelids. It is most commonly linked to long-term contact lens wear, but can also result from ocular prostheses, exposed sutures, or allergic triggers. Symptoms such as itching, redness, mucus discharge, and blurred vision significantly impact patient comfort and adherence to vision correction solutions.
Download Full PDF Sample Copy of…
More Releases for Exophthalmos
Cystinuria Market to Reach USD 2.5 Billion by 2034
Cystinuria is a rare inherited metabolic disorder characterized by defective renal transport of certain amino acids, particularly cystine, which leads to the formation of recurrent kidney stones. This autosomal recessive condition is caused by mutations in the SLC3A1 and SLC7A9 genes and affects approximately 1 in 7,000 to 1 in 10,000 individuals worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71685
Although not life-threatening when managed effectively, cystinuria poses a…
Chlamydia Infections Clinical Trials 2024: FDA Approvals, Clinical Trials, Thera …
(Albany, USA) DelveInsight's, "Chlamydia Infections Pipeline Insight, 2024," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chlamydia Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Chlamydia Infections Pipeline Report, detailed description of…
Usher Syndrome Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials …
(Albany, United States) As per DelveInsight's assessment, globally, Usher Syndrome pipeline constitutes 5+ key companies continuously working towards developing 7+ Usher Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Usher Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Usher Syndrome Market.
The Usher Syndrome Pipeline report embraces in-depth commercial…
Bullous Pemphigoid Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, T …
(Albany, United States) As per DelveInsight's assessment, globally, Bullous pemphigoid pipeline constitutes 4+ key companies continuously working towards developing 4+ Bullous pemphigoid treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Bullous pemphigoid Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bullous pemphigoid Market.
The Bullous pemphigoid Pipeline report embraces in-depth commercial…
Ox40 Antibody Market Size, Share, Top Players, Developments, Growth Outlook 2024 …
This report segments the Ox40 Antibody Market comprehensively. The regional market sizes, concerning products by type, by application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Ox40 Antibody Market Size was estimated at 2.75 (USD Billion) in 2023. The Ox40…
Exophthalmos Market to Witness Growth by 2032, Estimates DelveInsight | Eyevance …
(Las Vegas, Nevada, USA) DelveInsight's "Exophthalmos Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Exophthalmos, historical and forecasted epidemiology as well as the Exophthalmos market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Exophthalmos market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Exophthalmos market size from 2019…
